deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT02648997

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progressive/Recurrent Meningioma

Sponsor: Bristol-Myers Squibb

Conditions Meningiomas
Interventions External Beam RT Ipilimumab - 1 mg/kg Ipilimumab - 3 mg/kg Nivolumab - 1 mg/kg Nivolumab - 240 mg Nivolumab - 3 mg/kg Nivolumab - 480 mg
Updated 17 times since 2017 Last updated: Jan 7, 2026 Started: Mar 31, 2016 Primary completion: Dec 1, 2024 Completion: Jun 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Meningiomas and is currently ongoing. Bristol-Myers Squibb leads this study, which shows 17 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jun 2019 · 9 months · monthly snapshot~Jun 2019 – ~Apr 2020 · 10 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jan 2022 · 10 months · monthly snapshot~Jan 2022 – ~Feb 2023 · 13 months · monthly snapshot~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Feb 2026 · 13 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 12 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Feb 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  3. Jan 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  4. Mar 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  6. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  8. Jun 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  9. Sep 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  11. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Dana-Farber Cancer Institute
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations